Proteostasis Therapeutics Inc (NASDAQ:PTI) – Stock analysts at Leerink Swann raised their FY2018 earnings per share estimates for Proteostasis Therapeutics in a report released on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the company will earn ($1.49) per share for the year, up from their previous estimate of ($1.57). Leerink Swann currently has a “Outperform” rating and a $9.00 target price on the stock. Leerink Swann also issued estimates for Proteostasis Therapeutics’ FY2019 earnings at ($1.18) EPS and FY2020 earnings at ($1.20) EPS.

Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. The business had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%.

Separately, Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th.

Shares of Proteostasis Therapeutics (NASDAQ:PTI) opened at $2.52 on Monday. Proteostasis Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $16.67.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP bought a new position in shares of Proteostasis Therapeutics during the second quarter worth $254,000. Jennison Associates LLC boosted its position in shares of Proteostasis Therapeutics by 6.2% during the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock worth $9,713,000 after purchasing an additional 120,575 shares in the last quarter. FMR LLC boosted its position in shares of Proteostasis Therapeutics by 2.3% during the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after purchasing an additional 66,111 shares in the last quarter. Bain Capital Public Equity Management LLC bought a new position in shares of Proteostasis Therapeutics during the second quarter worth $1,233,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Proteostasis Therapeutics by 17.3% during the first quarter. Bank of New York Mellon Corp now owns 34,964 shares of the company’s stock worth $273,000 after purchasing an additional 5,153 shares in the last quarter. 68.08% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “FY2018 EPS Estimates for Proteostasis Therapeutics Inc (PTI) Lifted by Leerink Swann” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/04/fy2018-eps-estimates-for-proteostasis-therapeutics-inc-pti-lifted-by-leerink-swann.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.